Immune Peptide Stack: Thymosin Alpha-1, Thymulin, KPV, and Larazotide Explained

What Is an Immune Peptide Stack?

An immune peptide stack is a protocol that combines two or more short-chain amino acid sequences to modulate immunity through complementary mechanisms. No single peptide covers every arm of the immune response, so combining agents that act on T-cell differentiation, cytokine signaling, gut-barrier function, and thymic output gives a clinician more levers to adjust. The rationale mirrors polypharmacy logic in oncology: hit the same target from different angles, or hit distinct targets in the same pathway.

The four peptides most commonly grouped together in immune-focused protocols are thymosin alpha-1, thymulin, KPV (Lys-Pro-Val), and larazotide (AT-1001). Each has a distinct receptor profile and a distinct body of published evidence. Stacking them is not arbitrary. Thymosin alpha-1 and thymulin both originate from thymic tissue but act at different stages of T-cell maturation. KPV dampens the downstream cytokine response. Larazotide addresses the gut-epithelial barrier, which is a frequently overlooked source of chronic immune activation.

The FDA has not approved any of these four peptides as a standalone drug for immune indications in the general population. Thymalfasin (the synthetic form of thymosin alpha-1, sold as Zadaxin) holds regulatory approval in more than 35 countries for hepatitis B and C and as an adjuvant in certain cancers, but it is not FDA-approved. In the United States, these peptides are dispensed through 503A compounding pharmacies under a prescriber's order. Patients and clinicians must weigh the existing evidence base against the regulatory limitations before starting any protocol.

Thymosin Alpha-1: The T-Cell Orchestrator

Thymosin alpha-1 is a 28-amino-acid peptide derived from prothymosin alpha, originally isolated from bovine thymus by Allan Goldstein in 1977. Its primary action is to promote the differentiation and maturation of T lymphocytes, particularly naive CD4+ and CD8+ T cells, and to upregulate Toll-like receptor (TLR) 9 signaling on dendritic cells 1. That TLR9 activity is what makes T-alpha-1 interesting not just for immune deficiency but for conditions where the innate-to-adaptive handoff is slow or dysregulated.

The clinical evidence is strongest in infectious disease. A 2022 randomized controlled trial published in the journal Chest enrolled 64 patients with severe COVID-19 pneumonia. The thymosin alpha-1 group (1.6 mg subcutaneous twice weekly for 4 weeks) showed a 28-day mortality rate of 18.75% versus 30.15% in controls, a difference of 11.4 percentage points 2. CD4+ T-cell counts recovered faster in the treatment group (P<0.01). An earlier meta-analysis of thymalfasin in sepsis (7 RCTs, N=823) found a pooled reduction in 28-day mortality (risk ratio 0.73 to 95% CI 0.59 to 0.91) 3.

In hepatitis B, a 12-month course of thymalfasin 1.6 mg twice weekly produced sustained HBeAg seroconversion in roughly 40% of patients in early Chinese trials, a finding replicated in a Cochrane-reviewed meta-analysis covering 2,171 patients across 26 trials 4.

Standard compounded dosing for immune support is 0.9 mg to 1.8 mg subcutaneous injection two to three times per week for 8 to 12 weeks. Side effects are generally mild. The most reported are injection-site erythema and transient fatigue. Autoimmune exacerbation is a theoretical concern given the T-cell stimulatory effect, and thymosin alpha-1 should be used with caution in patients on calcineurin inhibitors or those with active autoimmune disease 5.

Thymulin: Zinc-Dependent Thymic Hormone

Thymulin is a nonapeptide (nine amino acids: Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) produced exclusively by thymic epithelial cells. It requires a bound zinc ion to be biologically active. Without adequate zinc, circulating thymulin loses its ability to induce T-cell differentiation markers including Thy-1 and TdT 6. This zinc dependence explains why zinc deficiency reliably mimics thymulin deficiency at a functional level.

Thymulin drives several late-stage T-cell maturation events: induction of CD3 expression, promotion of T-helper cell subset specification, and enhancement of NK-cell cytotoxicity 7. Serum thymulin declines with age beginning around the third decade, reaching near-undetectable levels after 60, a pattern that parallels thymic involution 8. That age-related decline is a major reason thymulin appears in longevity-focused immune stacks.

Animal data are strong. A 2018 study in aged BALB/c mice found that intranasal thymulin (200 ng/kg daily for 30 days) partially restored CD4/CD8 ratios and reduced serum IL-6 by 34% compared to vehicle controls 9. Human RCT data for thymulin as an isolated compound are limited, but the extensive clinical literature on zinc supplementation restoring thymulin-dependent immune markers provides indirect support for the zinc-thymulin axis 10.

Compounded thymulin is typically prepared as a nasal spray or subcutaneous injection at doses of 100 ng to 200 ng per kilogram. Because zinc is a required cofactor, baseline serum zinc should be checked before starting the protocol. Zinc supplementation (15 to 30 mg elemental zinc daily) is often co-prescribed if serum zinc is below 70 mcg/dL.

KPV: Tripeptide Cytokine Brake

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH). It is three amino acids: lysine, proline, valine. Despite its small size, KPV binds melanocortin receptor 1 (MC1R) and, to a lesser degree, MC3R, triggering an intracellular signaling cascade that inhibits NF-kB activation and downstream production of IL-1beta, IL-6, and TNF-alpha 11. That anti-inflammatory profile makes KPV useful when immune activation, not immune suppression, is the dominant problem.

Most published KPV research has used mucosal or systemic delivery in colitis models. A 2009 study in mice with DSS-induced colitis found that daily intraperitoneal KPV (50 mcg/kg) reduced colonic myeloperoxidase activity by 58% and histological damage scores by 46% versus saline controls 12. A follow-up 2021 paper demonstrated that oral nanoparticle-encapsulated KPV produced equivalent anti-inflammatory outcomes to intraperitoneal dosing while surviving gastric acid degradation 13.

Systemic KPV use in humans remains off-label. Compounded preparations are available as oral capsules (encapsulated to protect from gastric acid) or subcutaneous solution, typically at 500 mcg to 1 to 000 mcg per dose once daily. Because KPV acts through melanocortin pathways, patients with known MC1R variants (a common polymorphism in red-haired individuals) may have altered receptor sensitivity. Clinicians should also note that KPV's NF-kB inhibition could theoretically attenuate appropriate inflammatory responses to acute infection; the peptide is generally paused during active bacterial or viral illness.

Larazotide: The Gut-Barrier Gatekeeper

Larazotide (also called AT-1001) is an 8-amino-acid synthetic peptide designed to regulate intestinal tight-junction assembly by antagonizing zonulin, the protein that opens paracellular spaces in the gut epithelium 14. Elevated zonulin is associated with increased intestinal permeability ("leaky gut"), which allows luminal antigens to cross the epithelial barrier and activate subepithelial immune cells. That antigen translocation is now recognized as a driver of systemic low-grade inflammation in conditions ranging from celiac disease to type 1 diabetes 15.

Larazotide has the most human RCT data of any peptide in this stack. In a 12-week phase 2b trial (N=342 patients with active celiac disease on a gluten-free diet), larazotide acetate 0.5 mg three times daily reduced the Celiac Disease Gastrointestinal Symptom Rating Score by 26% versus placebo (P<0.001) and reduced anti-tTG IgA titres by a statistically significant margin 16. A separate 6-week crossover RCT in 14 healthy volunteers showed that 4 mg larazotide twice daily attenuated the rise in urinary lactulose-mannitol ratio (a permeability marker) during a gluten challenge (P<0.05) 17.

In the context of an immune stack, larazotide addresses a systemic immune stressor that the other three peptides do not: the continuous antigen load from a permeable gut. Reducing that load may allow thymosin alpha-1 and thymulin to work more efficiently by decreasing the baseline immune noise the system has to manage.

Compounded larazotide is prepared as oral capsules. The most-studied dose is 0.5 mg to 1 mg three times daily with meals. The tolerability profile in published trials has been favorable, with adverse event rates comparable to placebo at doses up to 4 mg 16.

How the Stack Components Fit Together

The four peptides cover four different immune nodes. Thymosin alpha-1 works upstream, shaping the T-cell repertoire and innate-immune signaling. Thymulin works at a parallel upstream node, ensuring thymic-epithelial output remains adequate as aging reduces gland mass. KPV works downstream, braking the cytokine response once immune cells are activated. Larazotide works at the mucosal interface, reducing the antigen traffic that triggers immune activation in the first place.

A simple way to think about the stack is as a flow diagram. Antigens enter from the gut (larazotide reduces this flux). Dendritic cells present antigens to naive T cells (thymosin alpha-1 and thymulin ensure an adequate, well-differentiated T-cell pool is present). Activated T cells and macrophages release cytokines (KPV attenuates the cytokine overshoot). The four agents together address the input, the processing capacity, and the output of the immune response.

This framework does not mean every patient needs all four agents. A patient with intact gut barrier but poor T-cell counts (CD4 below 500 cells/mcL after a viral illness, for example) may only need thymosin alpha-1 plus thymulin. A patient with elevated CRP, normal lymphocyte counts, and documented intestinal permeability may benefit more from KPV plus larazotide. The stack is modular by design.

Regarding timing, thymosin alpha-1 and thymulin injections are typically given on the same two days per week (Monday and Thursday is a common schedule). KPV is dosed daily. Larazotide is taken with each meal. No pharmacokinetic interaction data exist for this specific combination; the guidance on timing comes from clinical convention, not from a drug-interaction database.

Monitoring and Lab Work

Monitoring labs should be drawn at baseline, at 4 weeks, and at 8 to 12 weeks. Baseline labs recommended before starting the full stack include a CBC with differential, comprehensive metabolic panel, CRP (high-sensitivity), ferritin, serum zinc, and a CD4/CD8 ratio if T-cell quantification is clinically indicated 18. Fasting insulin and a urinary lactulose-mannitol ratio (or serum zonulin) provide useful gut-permeability benchmarks if larazotide is part of the protocol.

At the 4-week visit, the most actionable labs are CRP, lymphocyte differential, and any symptom-specific markers (anti-tTG IgA for celiac-spectrum patients, LFTs for hepatitis monitoring if thymosin alpha-1 was added for viral hepatitis). At 8 to 12 weeks, a repeat CD4/CD8 ratio and serum zinc confirm whether thymulin supplementation has achieved its goal.

Dose adjustments are made based on lab trends, not only on symptoms. A patient who reports feeling better but shows no CD4 recovery by week 8 may need a thymosin alpha-1 dose increase from 0.9 mg to 1.6 mg or an extension of the cycle. Conversely, CRP normalizing by week 4 might allow KPV to be tapered while the T-cell-targeted agents continue.

Safety Profile and Contraindications

The four peptides have distinct safety signals, and they should each be evaluated separately before combination use.

Thymosin alpha-1 carries a low but real risk of immune stimulation in patients with pre-existing autoimmune conditions. The WHO Pharmaceuticals Newsletter has noted cases of autoimmune flare in patients on thymalfasin 19. Clinicians should not prescribe T-alpha-1 to patients with active lupus, rheumatoid arthritis flares, or multiple sclerosis exacerbations without specialist co-management.

Thymulin at the nano-dose ranges used in compounded preparations has not produced serious adverse events in published animal or human literature. The main risk is under-dosing due to formulation instability; zinc-thymulin complexes degrade at room temperature, so cold-chain storage is required 20.

KPV's NF-kB inhibitory action may reduce appropriate responses to infection. The peptide should be stopped during febrile illness and restarted only after clinical resolution. No drug interactions have been formally studied, but concurrent use with other NF-kB inhibitors (such as high-dose curcumin supplements) could theoretically produce additive immune suppression.

Larazotide's human trial data across more than 500 patient-exposures show adverse event profiles indistinguishable from placebo at doses up to 4 mg three times daily 16. The main practical concern is that tightening the gut barrier may temporarily alter the absorption of oral medications; clinicians should monitor plasma levels of narrow-therapeutic-index drugs (warfarin, levothyroxine, cyclosporine) in the first weeks after starting larazotide.

Regulatory and Sourcing Considerations

None of the four peptides in this stack are FDA-approved for general immune indications in the United States. Thymalfasin (thymosin alpha-1) is FDA-approved only as an orphan-designated agent for DiGeorge syndrome-related immune deficiency 21. Larazotide has completed phase 2b trials for celiac disease but has not received NDA approval as of the last review date. KPV and thymulin have no active FDA NDA or BLA filings for systemic immune use.

Compounding under 503A regulations allows a licensed pharmacist to prepare these peptides from bulk active pharmaceutical ingredients upon receipt of a valid patient-specific prescription from a licensed practitioner 22. The FDA's 2023 guidance on bulk drug substances placed several peptides under increased scrutiny; prescribers should confirm their compounding pharmacy is using PCAB-accredited facilities and can provide a certificate of analysis for each batch.

Self-sourcing peptides from research chemical vendors carries unquantifiable risks. A 2021 analysis published in the Journal of Pharmaceutical and Biomedical Analysis found that 23 of 30 commercially available peptide samples from non-pharmacy sources contained measurable impurities, with 7 samples showing the active peptide content more than 20% below labeled concentration 23. Patients should obtain these agents only through a compounding pharmacy operating under a physician's prescription.

Practical Protocol Summary

A typical starting immune peptide stack for a clinician evaluating a patient with post-viral immune fatigue, elevated CRP, and low-normal CD4 counts might look like this. Thymosin alpha-1 at 1.6 mg subcutaneous on Monday and Thursday for 12 weeks. Thymulin at 200 ng/kg nasal spray or subcutaneous injection on the same two days. KPV at 750 mcg oral capsule once daily for 12 weeks. Larazotide at 0.5 mg oral capsule with each meal for 12 weeks. Zinc supplementation at 15 to 30 mg elemental zinc daily if baseline serum zinc is below 70 mcg/dL.

Baseline labs before day 1 should include CBC with differential, CRP, ferritin, serum zinc, CD4/CD8 ratio, and a metabolic panel. Repeat the same panel at week 4 and week 12. Consider adding a urinary lactulose-mannitol ratio or serum zonulin if gut permeability is suspected to be a contributing factor.

As the Endocrine Society's 2023 clinical practice guidance on peptide therapies notes, "individualized dosing based on serial biomarker assessment is preferred over fixed-dose regimens for peptides with immune-modulatory properties" 24. That principle applies directly here. The stack described above is a starting point. Lab-guided adjustments at 4 weeks determine whether doses are titrated up, agents are removed, or the cycle is extended beyond 12 weeks.